{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:03:18Z","timestamp":1784606598741,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-024-04799-4","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T17:01:18Z","timestamp":1709398878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-6798","authenticated-orcid":false,"given":"Naoki","family":"Wada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Mizunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotona","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyu","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoken","family":"Tsunekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Nagabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Iuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadasu","family":"Motoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Kakizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"4799_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11884-016-0344-9","volume":"11","author":"WS Reynolds","year":"2016","unstructured":"Reynolds WS, Fowke J, Dmochowski R (2016) The burden of overactive bladder on US public health. Curr Bladder Dysfunct Rep 11:8\u201313","journal-title":"Curr Bladder Dysfunct Rep"},{"key":"4799_CR2","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/j.1464-410X.2005.05835.x","volume":"96","author":"Y Homma","year":"2005","unstructured":"Homma Y, Yamaguchi O, Hayashi K et al (2005) An epidemiological survey of overactive bladder symptoms in Japan. BJU Int 96:1314\u20131318","journal-title":"BJU Int"},{"key":"4799_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1002\/nau.25037","volume":"41","author":"J Zillioux","year":"2022","unstructured":"Zillioux J, Welk B, Suskind AM et al (2022) SUFU white paper on overactive bladder anticholinergic medications and dementia risk. Neurourol Urodyn 41:1928\u20131933","journal-title":"Neurourol Urodyn"},{"key":"4799_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0090-4295(01)01635-1","volume":"59","author":"O Yamaguchi","year":"2002","unstructured":"Yamaguchi O (2002) \u03b23-adrenoceptors in human detrusor muscle. Urology 59:25\u201329","journal-title":"Urology"},{"key":"4799_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/01.ju.0000067621.62736.7c","volume":"170","author":"M Nomiya","year":"2003","unstructured":"Nomiya M, Yamaguchi O (2003) A quantitative analysis of mRNA expression of \u03b11 and \u03b2-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 170:649\u2013653","journal-title":"J Urol"},{"key":"4799_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1038\/sj.bjp.0702358","volume":"126","author":"Y Igawa","year":"1999","unstructured":"Igawa Y, Yamazaki Y, Takeda H et al (1999) Functional and molecular biological evidence for a possible \u03b23-adrenoceptor in the human detrusor muscle. Br J Pharmacol 126:819\u2013825","journal-title":"Br J Pharmacol"},{"key":"4799_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","volume":"74","author":"C Kelleher","year":"2018","unstructured":"Kelleher C, Hakimi Z, Zur R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74:324\u2013333","journal-title":"Eur Urol"},{"key":"4799_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/nau.23863","volume":"38","author":"J Wang","year":"2019","unstructured":"Wang J, Zhou Z, Cui Y et al (2019) Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn 38:22\u201330","journal-title":"Neurourol Urodyn"},{"key":"4799_CR9","first-page":"2022-4-2","volume":"11","author":"M Kennelly","year":"2022","unstructured":"Kennelly M, Wielage R, Shortino D et al (2022) Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis. Drugs Context 11:2022-4\u20132","journal-title":"Drugs Context"},{"key":"4799_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12475","author":"W He","year":"2023","unstructured":"He W, Zhang Y, Huang G et al (2023) Efficacy and safety of vibegron compared with mirabegron for overactive bladder: a systematic review and network meta-analysis. Low Urin Tract Symptoms. https:\/\/doi.org\/10.1111\/luts.12475","journal-title":"Low Urin Tract Symptoms"},{"key":"4799_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/iju.12220","volume":"21","author":"Y Homma","year":"2014","unstructured":"Homma Y, Fujimura T (2014) Linguistic validation of the English version of the overactive bladder symptom score. Int J Urol 21:229","journal-title":"Int J Urol"},{"key":"4799_CR12","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/bju.12649","volume":"113","author":"O Yamaguchi","year":"2014","unstructured":"Yamaguchi O, Marui E, Kakizaki H et al (2014) Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 113:951\u2013960","journal-title":"BJU Int"},{"key":"4799_CR13","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","volume":"73","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Takeda M, Gotoh M et al (2018) Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study. Eur Urol 73:783\u2013790","journal-title":"Eur Urol"},{"key":"4799_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s13318-013-0133-1","volume":"39","author":"W Krauwinkel","year":"2014","unstructured":"Krauwinkel W, Dickinson J, Schaddelee M et al (2014) The effect of mirabegron, a potent and selective \u03b23-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet 39:43\u201352","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4799_CR15","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s11255-020-02536-5","volume":"52","author":"Z Jian","year":"2020","unstructured":"Jian Z, Yuan C, Li H et al (2020) Vibegron 50 mg is the optimal algorithm in the pharmacologic management of overactive bladder: outcomes from a systematic review and meta-analysis. Int Urol Nephrol 52:2215\u20132221","journal-title":"Int Urol Nephrol"},{"key":"4799_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/pharmrev.121.000523","volume":"75","author":"MC Michel","year":"2023","unstructured":"Michel MC, Cardozo L, Chermansky CJ et al (2023) Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders. Pharmacol Rev 75:554\u2013674","journal-title":"Pharmacol Rev"},{"issue":"96","key":"4799_CR17","doi-asserted-by":"publisher","first-page":"100674","DOI":"10.1016\/j.curtheres.2022.100674","volume":"14","author":"BM Brucker","year":"2022","unstructured":"Brucker BM, King J, Mudd PN Jr et al (2022) Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors. Curr Ther Res Clin Exp 14(96):100674","journal-title":"Curr Ther Res Clin Exp"},{"key":"4799_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","volume":"175","author":"M Kinjo","year":"2023","unstructured":"Kinjo M, Masuda K, Nakamura Y et al (2023) Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study. Urology 175:67\u201373","journal-title":"Urology"},{"key":"4799_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/luts.12480","volume":"15","author":"H Sato","year":"2023","unstructured":"Sato H, Otsuka S, Tsukada S (2023) Mirabegron versus vibegron in previously untreated female patients with overactive bladder: a randomized, single-clinic, open-label trial. Low Urin Tract Symptoms 15:129\u2013138","journal-title":"Low Urin Tract Symptoms"},{"key":"4799_CR20","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/luts.12391","volume":"13","author":"S Mukai","year":"2021","unstructured":"Mukai S, Nomi M, Yamada S et al (2021) The 1-year continuation rate and discontinuation factors of vibegron and mirabegron: a retrospective comparative study in a rehabilitation hospital in Japan. Lower Urinary Tract Symptoms 13:448\u2013455","journal-title":"Lower Urinary Tract Symptoms"},{"key":"4799_CR21","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/nau.23050","volume":"36","author":"K Torimoto","year":"2017","unstructured":"Torimoto K, Matsushita C, Yamada A et al (2017) Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: a randomized crossover study (the MICRO study). Neurourol Urodyn 36:1097\u20131103","journal-title":"Neurourol Urodyn"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04799-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04799-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:21:27Z","timestamp":1735852887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04799-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4799"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04799-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"12 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Naoki Wada received speaker honorarium from Astellas Pharma Inc. Hidehiro Kakizaki received speaker honorarium from Astella Pharma Inc., Kyorin and Kissei. The other authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The ethics committee of Asahikawa Medical University approved the study protocol (approval number:18174).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study before enrollment. This study was registered at  as UMIN000034720.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"113"}}